The University of Dundee, in collaboration with the Michael J. Fox Foundation, is embarking on a groundbreaking Parkinson’s research initiative focused on the development of therapeutic strategies targeting LRRK2.
This initiative, named the LRRK2 Investigative Therapeutics Exchange (LITE), represents a significant step forward in the understanding and treatment of inherited Parkinson’s disease.
With substantial grant funding amounting to tens of millions of pounds, LITE aims to bridge the gap between cutting-edge advancements in basic science and the crucial drug development efforts led by industry partners.
By bringing together expertise from academia and the pharmaceutical sector, this initiative holds the promise of accelerating the translation of scientific discoveries into tangible treatments for Parkinson’s disease.
Heading the LITE initiative is Professor Dario Alessi, a renowned authority in kinase research with a particular focus on LRRK2. Professor Alessi, who leads a dedicated laboratory at the University of Dundee, brings a wealth of experience and expertise to this project. Moreover, as the head of the Division of Signal Transduction Therapy, a collaborative platform uniting top researchers and leading pharmaceutical companies, Professor Alessi is well-positioned to drive forward the mission of LITE.
Comments